Welcome to our dedicated page for Adicet Bio news (Ticker: $ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adicet Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adicet Bio's position in the market.
Adicet Bio, Inc. (Nasdaq: ACET) will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference in New York. Chen Schor, President and CEO, will present on May 14, 2024, at 1:30 p.m. ET. The presentation can be accessed on the Investors section of Adicet Bio's website.
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award on April 30, 2024, to a new employee. The award consists of non-qualified stock options to purchase 7,800 shares at $1.49 per share. Vesting occurs over four years, with one-fourth vesting after one year and the rest in monthly installments. The award was granted outside Adicet's equity plans under the Inducement Plan.
